Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Preferred Stock Liabilities: 2013-2016

Historic Preferred Stock Liabilities for KalVista Pharmaceuticals (KALV) over the last 4 years, with Apr 2016 value amounting to $58.6 million.

  • KalVista Pharmaceuticals' Preferred Stock Liabilities was N/A to $39.6 million in Q1 2015 from the same period last year, while for Mar 2015 it was $39.6 million, marking a year-over-year change of. This contributed to the annual value of $58.6 million for FY2016, which is 128.88% up from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Preferred Stock Liabilities of $58.6 million as of FY2016, which was up 128.88% from $25.6 million recorded in FY2015.
  • Over the past 5 years, KalVista Pharmaceuticals' Preferred Stock Liabilities peaked at $58.6 million during FY2016, and registered a low of $25.6 million during FY2015.
  • For the 3-year period, KalVista Pharmaceuticals' Preferred Stock Liabilities averaged around $41.3 million, with its median value being $39.6 million (2014).
  • Data for KalVista Pharmaceuticals' Preferred Stock Liabilities shows a peak YoY skyrocketed of 128.88% (in 2016) over the last 5 years.
  • Yearly analysis of 4 years shows KalVista Pharmaceuticals' Preferred Stock Liabilities stood at $39.6 million in 2013, then remained steady at $39.6 million in 2014, then reached $25.6 million in 2015, then skyrocketed by 128.88% to $58.6 million in 2016.